Skip to main content
. 2021 Jun 2;44(6):699–709. doi: 10.1007/s40264-021-01065-z

Fig. 3.

Fig. 3

Histogram of propensity scores for the ustekinumab and adalimumab cohorts based on revised analyses; incident users in the ever-exposed population (post hoc analyses)